Top Markets
#1 QuantixAI QuantixAI +32.46%
#2 MowCat MowCat +27.15%
#3 Prom Prom +19.93%
#4 Wrapped STX (Velar) Wrapped STX (Velar) +17.98%
#5 Versatize Coin Versatize Coin +16.67%
#6 Tutorial Tutorial +15.31%
#7 UnifAI Network UnifAI Network +14.50%
#8 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +14.28%
#9 Pons Pons +10.30%
#10 Wrapped NXM Wrapped NXM +9.46%
Coin of the day
QuantixAI QuantixAI
Settings
Language
ENGLISH
Currency
USD
Theme
ZIOPHARM Oncology, Inc. ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc.

ZIOP
Rank in Stocks #20772
ZIOPHARM Oncology, Inc. is a clinical-stage biopharmaceutical firm dedicated to... ZIOPHARM Oncology, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing innovative immuno-oncology treatments for cancer patients. The company leverages its proprietary Sleeping Beauty platform, which employs non-viral genetic engineering to modify T-cells outside the body using a transposon/transposase system for subsequent infusion. Additionally, ZIOPHARM is advancing its Controlled IL-12 technology, designed to precisely regulate the expression of interleukin-12 (IL-12), a key immune system regulator, to direct the patient's immune response against cancer cells. Its pipeline features several promising therapeutic candidates, including T-cell receptor (TCR) plus T-cell therapies aimed at solid tumors, chimeric antigen receptor (CAR) T-cell therapies specifically targeting CD19 for hematologic malignancies, and Ad-RTS-hIL-12 combined with veledimex, a gene delivery system for controlled IL-12 production under investigation for treating recurrent adult glioblastoma multiforme. ZIOPHARM maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., and research and development agreements, alongside patent licensing, with institutions such as The University of Texas MD Anderson Cancer Center and the National Cancer Institute. The company's headquarters are located in Boston, Massachusetts.
Share Price
$0.8657
Last synced: 2022-01-26
Market Cap
$122.22M
Change (1 day)
-0.88%
Change (1 year)
0.00%
Country
US
Trade ZIOPHARM Oncology, Inc. (ZIOP)

Category

Healthcare
Operating Margin for ZIOPHARM Oncology, Inc. (ZIOP)
Operating Margin as of 2026 TTM: 0.00%
According to ZIOPHARM Oncology, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for ZIOPHARM Oncology, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.